Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
COGT 
Cogent Biosciences Inc (COGT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: COGT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $20.36
1 Year Target Price $20.36
| 5 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.72% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.69B USD | Price to earnings Ratio - | 1Y Target Price 20.36 |
Price to earnings Ratio - | 1Y Target Price 20.36 | ||
Volume (30-day avg) 12 | Beta 0.36 | 52 Weeks Range 3.72 - 12.97 | Updated Date 08/29/2025 |
52 Weeks Range 3.72 - 12.97 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.5867 | Actual -0.64 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -53.15% | Return on Equity (TTM) -107.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1618310615 | Price to Sales(TTM) 1320.63 |
Enterprise Value 1618310615 | Price to Sales(TTM) 1320.63 | ||
Enterprise Value to Revenue 925.41 | Enterprise Value to EBITDA -3.89 | Shares Outstanding 139700992 | Shares Floating 102748660 |
Shares Outstanding 139700992 | Shares Floating 102748660 | ||
Percent Insiders 0.04 | Percent Institutions 105.23 |
Upturn AI SWOT
Cogent Biosciences Inc
Company Overview
History and Background
Cogent Biosciences, Inc. (formerly Forma Therapeutics) is a biotechnology company focused on developing precision therapies for genetically defined diseases. Founded in 2014, the company has evolved from a broader drug discovery platform to a more focused precision oncology approach. A key milestone was the transition to Cogent Biosciences and the prioritization of bezuclastinib (formerly CGT-9486) in systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST).
Core Business Areas
- Precision Oncology: Cogent Biosciences focuses on developing kinase inhibitors for genetically defined cancers. Their lead program, bezuclastinib, targets the KIT D816V mutation, a driver of systemic mastocytosis and certain GISTs.
- Systemic Mastocytosis (SM): Developing bezuclastinib for advanced systemic mastocytosis (AdvSM) and indolent systemic mastocytosis (ISM).
- Gastrointestinal Stromal Tumors (GIST): Developing bezuclastinib for patients with GIST harboring specific KIT mutations, particularly after failure of other therapies.
Leadership and Structure
Andrew Robbins serves as the President and CEO. The company has a typical biotech structure with departments focused on research, development, clinical operations, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Bezuclastinib (CGT-9486): A selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as KIT exon 17 mutations. Currently in clinical development for advanced systemic mastocytosis (AdvSM) and indolent systemic mastocytosis (ISM), and GIST. While not yet approved, bezuclastinib is projected to be a significant competitor to Blueprint Medicines' Ayvakit (avapritinib) in AdvSM and Novartis' Gleevec and newer TKIs in GIST. Market share will depend on clinical trial outcomes and regulatory approvals. Competitors: Blueprint Medicines (Ayvakit), Novartis (Gleevec), Deciphera (Qinlock).
Market Dynamics
Industry Overview
The oncology market is characterized by high unmet needs and rapid innovation. Precision oncology, targeting specific genetic mutations, is a growing segment. Systemic mastocytosis and GIST are niche areas within oncology, representing smaller patient populations but significant opportunities for targeted therapies.
Positioning
Cogent Biosciences is positioning itself as a leader in precision therapies for KIT-driven diseases, specifically SM and GIST. Their selective kinase inhibitor, bezuclastinib, is designed to overcome the limitations of existing therapies. Their competitive advantage lies in the specificity and potency of bezuclastinib for the KIT D816V mutation and KIT exon 17 mutations.
Total Addressable Market (TAM)
The TAM for SM and GIST combined is estimated to be in the billions of dollars. The SM market is estimated to be $1-2 billion, and the GIST market is expected to be $3-5 billion. Cogent Biosciences is positioned to capture a significant share of these markets with bezuclastinib, assuming successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Highly selective kinase inhibitor (bezuclastinib)
- Strong preclinical and early clinical data
- Experienced management team
- Focus on genetically defined diseases
- Potential to address unmet needs in SM and GIST
Weaknesses
- Reliance on a single lead product (bezuclastinib)
- Clinical trial risks and regulatory hurdles
- Limited commercial infrastructure
- Relatively small company size
- Cash Burn Rate
Opportunities
- Successful clinical trials and regulatory approvals for bezuclastinib
- Expansion into other indications with KIT mutations
- Strategic partnerships with larger pharmaceutical companies
- Acquisition opportunities
- Expanding applications for Bezuclastinib
Threats
- Competition from existing therapies and emerging competitors
- Clinical trial failures
- Regulatory setbacks
- Pricing pressures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- BLUP
- NVS
- DCPH
Competitive Landscape
Cogent has a strong focus on specific gene mutations within SM and GIST, which differentiates them from BLUP, NVS and DCPH. These companies currently have a larger market share.
Major Acquisitions
Forma Therapeutics
- Year: 2020
- Acquisition Price (USD millions): 16.9
- Strategic Rationale: Reverse merger allowed COGT to become a public company.
Growth Trajectory and Initiatives
Historical Growth: Historically, Cogent has grown through acquisitions and the advancement of its pipeline.
Future Projections: Future growth is highly dependent on the success of bezuclastinib's clinical trials. Analyst estimates project significant revenue growth upon potential commercialization, but these are speculative and based on successful outcomes.
Recent Initiatives: Recent initiatives include advancing the bezuclastinib clinical program in SM and GIST, presenting clinical data at scientific conferences, and strengthening the management team.
Summary
Cogent Biosciences is a clinical-stage biotechnology company with a promising lead asset, bezuclastinib, targeting specific genetic mutations in SM and GIST. The company's success hinges on positive clinical trial outcomes and regulatory approvals. While possessing a focused strategy and potential for significant market share in niche areas, Cogent faces risks associated with clinical development, competition, and financial constraints. Future success depends heavily on the clinical data generated for Bezuclastinib, and any positive results will cause strong growth for Cogent.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cogent Biosciences Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2018-03-29 | President, CEO & Director Mr. Andrew R. Robbins M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 205 | Website https://www.cogentbio.com |
Full time employees 205 | Website https://www.cogentbio.com | ||
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.